Effect of pomegranate seed extract in rheumatoid arthritis

Evaluating the efficacy of capsules containing pomegranate seed extract in improving the symptoms of patients with rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220828055810N1

Enrollment

Registered

2022-11-11

Start date

2022-12-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: Intervention group: The patients will be received conventional drugs including 0.2 mg/kg/week methotrexate, 5 mg prednisolone 2 times a day and 200 mg pomegranate seed extract capsule

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of rheumatoid arthritis according to American College of Rheumatology criteria Moderate to severe rheumatoid arthritis according to DAS28 (disease Activity Score 28 (DAS-28) criteria Consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy Renal diseases Liver diseases Respiratory diseases Taking sex hormones Cancer

Design outcomes

Primary

Measure	Time frame
Erythrocyte sedimentation rate (ESR). Timepoint: before intervention and 2, 4, and 8 weeks after starting of treatment. Method of measurement: Measurement of ESR by Automated Analyser of sediment reader.;C reactive protein. Timepoint: before intervention and 2, 4, and 8 weeks after starting of treatment. Method of measurement: Using specific Kit and Immunoturbidimetry method.;Plasma level of Interleukin-17. Timepoint: before treatment and after end of treatment period. Method of measurement: By using specific laboratory Kit and ELISA reader.;Plasma level of Interleukin-6. Timepoint: before treatment and after end of treatment period (end of 8th week). Method of measurement: By using specific laboratory Kit and ELISA reader.;Count of tender joints (TJC). Timepoint: before and after the treatment (end of 8th week). Method of measurement: Based on the patient's symptoms and the patient's examination by a specialist.;Count of swollen joints (SJC). Timepoint: before and after the treatment (end of 8th week). Method of measurement: Based on the patient's symptoms and the patient's examination by a specialist.	—

Measure

Time frame

Erythrocyte sedimentation rate (ESR). Timepoint: before intervention and 2, 4, and 8 weeks after starting of treatment. Method of measurement: Measurement of ESR by Automated Analyser of sediment reader.;C reactive protein. Timepoint: before intervention and 2, 4, and 8 weeks after starting of treatment. Method of measurement: Using specific Kit and Immunoturbidimetry method.;Plasma level of Interleukin-17. Timepoint: before treatment and after end of treatment period. Method of measurement: By using specific laboratory Kit and ELISA reader.;Plasma level of Interleukin-6. Timepoint: before treatment and after end of treatment period (end of 8th week). Method of measurement: By using specific laboratory Kit and ELISA reader.;Count of tender joints (TJC). Timepoint: before and after the treatment (end of 8th week). Method of measurement: Based on the patient's symptoms and the patient's examination by a specialist.;Count of swollen joints (SJC). Timepoint: before and after the treatment (end of 8th week). Method of measurement: Based on the patient's symptoms and the patient's examination by a specialist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactprofessor Ali Asghar Hemmati

Ahvaz University of Medical Sciences

hemmati_aa@yahoo.com+98 61 3392 7310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026